DCAT Research & Benchmarking
DCAT Research & Benchmarking
DCAT’s 2026 Study:
Creating Value Beyond Product and Price in the Pharma Customer-Supplier Relationship
The Drug, Chemical & Associated Technologies Association (DCAT) and its Research & Benchmarking Committee is pleased to make available to DCAT Member Companies its latest study, Creating Value Beyond Product and Price in the Pharma Customer-Supplier Relationship.
In a highly competitive environment, providing value beyond core deliverables of product and price is crucial for CDMOs and materials suppliers to gain and maintain an edge with their bio/pharma customers, but do bio/pharma companies and their suppliers agree on what constitutes value-added enhancements?
Gain valuable insights from the study, which provides a “buy-and-sell-side view” on:
- What Constitutes Value Creation? Are there particular services or situations for which value-added enhancements are more likely to be offered than for other services? Is there a trend to offer value-adding services more frequently? Less frequently?
- How is Value Creation Measured? When value-adding enhancements are proposed during the sourcing/procurement process, how formally are they evaluated? Is there a formal cost/benefit analysis done or is the evaluation more subjective?
DCAT Research & Benchmarking Report Archives
Click here to request a prior year report (see below for topics).
What Makes a Customer of Choice: Are Pharma Companies & Suppliers Aligned? (2025)
In today’s complex supply chain landscape, strong customer-supplier relations are a strategic must. Evaluating supplier performance is common, but what about the performance of customers to their suppliers? This report explores an all-important dynamic: What does it take to become a Preferred Customer or a “Customer of Choice” of suppliers, what benefits accrue, and are customers and suppliers aligned in their expectations?
The Emerging Role of AI in Supply Chain Management (2024)
Gain insight into how will AI change the way bio/pharma companies and their suppliers will do business, how AI is now being used in supply chain management, and its potential in furthering the customer-supplier relationship.
Envisioning Bio/Pharma Sourcing and Supply Chain Management in 2030 (2023)
Gain executive views on their vision for the supply-chain organization of the future: what bio/pharma sourcing and supply-chain functions will look like, how suppliers can prepare for changing customer expectations, and how the role of suppliers will evolve.
About DCAT Research & Benchmarking
DCAT Research & Benchmarking is a complimentary, value-added member benefit providing in-depth studies that examine the crucial issues impacting the bio/pharmaceutical business ecosystem and the bio/pharma customer—supplier relationship. DCAT Research & Benchmarking studies are developed by the DCAT Research & Benchmarking Committee, composed of member representatives with diverse industry experience, to identify the topics of greatest interest for DCAT Member Companies and is administered and prepared using an external research firm.
